Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-1.32% $3.75
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 96.20 mill |
EPS: | -0.0100 |
P/E: | -375.00 |
Earnings Date: | Nov 13, 2023 |
SharesOutstanding: | 25.65 mill |
Avg Daily Volume: | 0.0719 mill |
RATING 2024-03-28 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -375.00 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-63.79x |
Company: PE -375.00 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 3.56 - 3.94 ( +/- 5.15%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-13 | Gruber James R. | Buy | 144 677 | Stock Option (Right to buy) |
2024-02-13 | Adams Jennifer Mckie | Buy | 30 000 | Stock Option (Right to buy) |
2024-02-13 | Brynjelsen Sean | Buy | 438 633 | Stock Option (Right to buy) |
2024-02-13 | Casamento Charles J | Buy | 30 000 | Stock Option (Right to buy) |
2024-02-13 | Krempa David | Buy | 144 677 | Stock Option (Right to buy) |
INSIDER POWER |
---|
53.82 |
Last 96 transactions |
Buy: 4 266 352 | Sell: 3 981 653 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.75 (-1.32% ) |
Volume | 0.0557 mill |
Avg. Vol. | 0.0719 mill |
% of Avg. Vol | 77.39 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.